相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
James E. Neffendorf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The future of glycoprotein VI as an antithrombotic target
M. Zahid et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo
Marie-Pierre Gratacap et al.
BLOOD (2009)
Platelet glycoprotein VI-related clinical defects
Jane F. Arthur et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
X-linked Agammaglobulinemia - Report on a United States registry of 201 patients
Jerry A. Winkelstein et al.
MEDICINE (2006)
Tec regulates platelet activation by GPVI in the absence of Btk
BT Atkinson et al.
BLOOD (2003)
分享论文
